annual EBITDA:
-$247.37M-$98.74M(-66.43%)Summary
- As of today (July 1, 2025), AKRO annual EBITDA is -$247.37 million, with the most recent change of -$98.74 million (-66.43%) on December 31, 2024.
- During the last 3 years, AKRO annual EBITDA has fallen by -$146.64 million (-145.57%).
- AKRO annual EBITDA is now -1695.43% below its all-time high of -$13.78 million, reached on December 31, 2018.
Performance
AKRO EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$69.57M-$762.00K(-1.11%)Summary
- As of today (July 1, 2025), AKRO quarterly EBITDA is -$69.57 million, with the most recent change of -$762.00 thousand (-1.11%) on March 31, 2025.
- Over the past year, AKRO quarterly EBITDA has dropped by -$17.22 million (-32.89%).
- AKRO quarterly EBITDA is now -16425.18% below its all-time high of -$421.00 thousand, reached on March 31, 2018.
Performance
AKRO quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$264.59M-$17.22M(-6.96%)Summary
- As of today (July 1, 2025), AKRO TTM EBITDA is -$264.59 million, with the most recent change of -$17.22 million (-6.96%) on March 31, 2025.
- Over the past year, AKRO TTM EBITDA has dropped by -$88.97 million (-50.66%).
- AKRO TTM EBITDA is now -62748.69% below its all-time high of -$421.00 thousand, reached on March 31, 2018.
Performance
AKRO TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
AKRO EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -66.4% | -32.9% | -50.7% |
| 3 y3 years | -145.6% | -167.4% | -136.9% |
| 5 y5 years | -441.9% | -462.0% | -331.2% |
AKRO EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -145.6% | at low | -206.7% | +2.6% | -140.3% | at low |
| 5 y | 5-year | -441.9% | at low | -360.2% | +2.6% | -331.2% | at low |
| alltime | all time | -1695.4% | at low | <-9999.0% | +2.6% | <-9999.0% | at low |
AKRO EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$69.57M(+1.1%) | -$264.59M(+7.0%) |
| Dec 2024 | -$247.37M(+66.4%) | -$68.81M(-3.7%) | -$247.37M(+6.2%) |
| Sep 2024 | - | -$71.46M(+30.5%) | -$232.85M(+16.3%) |
| Jun 2024 | - | -$54.76M(+4.6%) | -$200.16M(+14.0%) |
| Mar 2024 | - | -$52.35M(-3.6%) | -$175.62M(+18.2%) |
| Dec 2023 | -$148.63M(+33.6%) | -$54.29M(+40.0%) | -$148.63M(+27.0%) |
| Sep 2023 | - | -$38.77M(+28.3%) | -$117.03M(+3.1%) |
| Jun 2023 | - | -$30.21M(+19.1%) | -$113.47M(+2.6%) |
| Mar 2023 | - | -$25.36M(+11.8%) | -$110.60M(-0.6%) |
| Dec 2022 | -$111.25M(+10.4%) | -$22.69M(-35.6%) | -$111.25M(-8.0%) |
| Sep 2022 | - | -$35.21M(+28.8%) | -$120.98M(+9.9%) |
| Jun 2022 | - | -$27.34M(+5.1%) | -$110.09M(-1.4%) |
| Mar 2022 | - | -$26.02M(-19.7%) | -$111.67M(+10.8%) |
| Dec 2021 | -$100.74M | -$32.41M(+33.3%) | -$100.77M(+2.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2021 | - | -$24.32M(-15.9%) | -$98.13M(+2.9%) |
| Jun 2021 | - | -$28.92M(+91.3%) | -$95.34M(+15.0%) |
| Mar 2021 | - | -$15.12M(-49.2%) | -$82.88M(+3.4%) |
| Dec 2020 | -$80.14M(+75.5%) | -$29.77M(+38.3%) | -$80.14M(+20.4%) |
| Sep 2020 | - | -$21.53M(+30.9%) | -$66.59M(+8.5%) |
| Jun 2020 | - | -$16.45M(+32.9%) | -$61.36M(+16.8%) |
| Mar 2020 | - | -$12.38M(-23.7%) | -$52.52M(+15.0%) |
| Dec 2019 | -$45.65M(+231.3%) | -$16.22M(-0.5%) | -$45.65M(+40.9%) |
| Sep 2019 | - | -$16.31M(+114.3%) | -$32.40M(+81.8%) |
| Jun 2019 | - | -$7.61M(+38.0%) | -$17.82M(-5.6%) |
| Mar 2019 | - | -$5.51M(+85.7%) | -$18.87M(+37.0%) |
| Dec 2018 | -$13.78M | -$2.97M(+71.9%) | -$13.78M(+27.5%) |
| Sep 2018 | - | -$1.73M(-80.1%) | -$10.81M(+19.0%) |
| Jun 2018 | - | -$8.66M(+1957.5%) | -$9.08M(+2057.5%) |
| Mar 2018 | - | -$421.00K | -$421.00K |
FAQ
- What is Akero Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Akero Therapeutics?
- What is Akero Therapeutics annual EBITDA year-on-year change?
- What is Akero Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Akero Therapeutics?
- What is Akero Therapeutics quarterly EBITDA year-on-year change?
- What is Akero Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Akero Therapeutics?
- What is Akero Therapeutics TTM EBITDA year-on-year change?
What is Akero Therapeutics annual EBITDA?
The current annual EBITDA of AKRO is -$247.37M
What is the all time high annual EBITDA for Akero Therapeutics?
Akero Therapeutics all-time high annual EBITDA is -$13.78M
What is Akero Therapeutics annual EBITDA year-on-year change?
Over the past year, AKRO annual EBITDA has changed by -$98.74M (-66.43%)
What is Akero Therapeutics quarterly EBITDA?
The current quarterly EBITDA of AKRO is -$69.57M
What is the all time high quarterly EBITDA for Akero Therapeutics?
Akero Therapeutics all-time high quarterly EBITDA is -$421.00K
What is Akero Therapeutics quarterly EBITDA year-on-year change?
Over the past year, AKRO quarterly EBITDA has changed by -$17.22M (-32.89%)
What is Akero Therapeutics TTM EBITDA?
The current TTM EBITDA of AKRO is -$264.59M
What is the all time high TTM EBITDA for Akero Therapeutics?
Akero Therapeutics all-time high TTM EBITDA is -$421.00K
What is Akero Therapeutics TTM EBITDA year-on-year change?
Over the past year, AKRO TTM EBITDA has changed by -$88.97M (-50.66%)